

Francesco Onida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3827970/publications.pdf>

Version: 2024-02-01

124
papers

4,711
citations

101384

36
h-index

102304

66
g-index

148
all docs

148
docs citations

148
times ranked

5208
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. <i>Blood</i> , 2002, 99, 840-849.	0.6	356
2	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÅ@zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
3	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
4	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
5	Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and SÅ@zary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 4492-4499.	0.8	191
6	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). <i>Journal of Clinical Oncology</i> , 2017, 35, 2157-2164.	0.8	183
7	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
8	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
9	Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. <i>Gut</i> , 2008, 57, 211-217.	6.1	142
10	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
11	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	3.8	136
12	<i>RAS</i> Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant. <i>Clinical Cancer Research</i> , 2010, 16, 2246-2256.	3.2	123
13	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. <i>Blood Cancer Journal</i> , 2015, 5, e333-e333.	2.8	117
14	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
15	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
16	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. <i>HemaSphere</i> , 2018, 2, e150.	1.2	91
17	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. <i>Blood</i> , 2013, 122, 4111-4118.	0.6	90
18	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and SÅ@zary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3347-3348.	0.8	85

#	ARTICLE	IF	CITATIONS
19	Characteristics and outcome of patients with Philadelphia chromosome negative,bcr/abl negative chronic myelogenous leukemia. <i>Cancer</i> , 2002, 95, 1673-1684.	2.0	82
20	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2116-2127.	6.3	79
21	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European prospective noninterventional study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	0.8	75
22	Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2004, 33, 1005-1009.	1.3	73
23	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
24	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	5.8	66
25	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
26	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. <i>Leukemia and Lymphoma</i> , 2007, 48, 1150-1160.	0.6	60
27	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. <i>Leukemia</i> , 2018, 32, 413-418.	3.3	58
28	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. <i>Haematologica</i> , 2021, 106, 375-383.	1.7	57
29	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> ,the, 2020, 7, e601-e612.	2.2	56
30	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. <i>Digestive and Liver Disease</i> , 2011, 43, 946-952.	0.4	53
31	Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. <i>Bone Marrow Transplantation</i> , 2017, 52, 53-58.	1.3	53
32	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. <i>Haematologica</i> , 2011, 96, 291-297.	1.7	51
33	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
34	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	0.6	43
35	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 885-890.	2.0	42
36	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. <i>Blood Cancer Journal</i> , 2015, 5, e270-e270.	2.8	39

#	ARTICLE	IF	CITATIONS
37	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2017, 177, 759-765.	1.2	38
38	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	1.7	36
39	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. <i>Haematologica</i> , 2013, 98, 1344-1352.	1.7	35
40	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , 2016, 5, 2740-2755.	1.3	34
41	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	0.6	29
42	Chronic myelomonocytic leukemia: myeloproliferative variant. <i>Psychophysiology</i> , 2004, 3, 218-26.	1.1	28
43	Reply to "COVID-19 in persons with haematological cancers" a focus on myeloid neoplasms and risk factors for mortality. <i>Leukemia</i> , 2020, 34, 1957-1960.	3.3	26
44	Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. <i>Frontiers in Immunology</i> , 2020, 11, 569381.	2.2	26
45	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. <i>PLoS ONE</i> , 2013, 8, e74368.	1.1	25
46	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	1.3	24
47	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	1.3	24
48	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dakota Trial. <i>Blood</i> , 2020, 136, 53-54.	0.6	24
49	Prognostic significance of monocytosis in patients with myeloproliferative disorders. <i>Leukemia and Lymphoma</i> , 2006, 47, 417-423.	0.6	23
50	Paclitaxel-Dependent Prolonged and Persistent Complete Remission Four Years from First Recurrence of Secondary Breast Angiosarcoma. <i>Tumori</i> , 2009, 95, 828-831.	0.6	22
51	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody "Begelomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	1.3	21
52	Metabolic syndrome in patients with hematological diseases. <i>Expert Review of Hematology</i> , 2012, 5, 439-458.	1.0	15
53	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	1.2	14
54	Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 650-655.	0.2	13

#	ARTICLE	IF	CITATIONS
55	OPO21 Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S014-S015.	0.6	13
56	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥ 60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	0.6	13
57	Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , 2013, 37, 809-815.	0.4	11
58	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: An Update on Risk Stratification, Molecular Genetics, and Therapeutic Approaches Including Allogeneic Hematopoietic Stem Cell Transplantation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e398-e412.	1.8	11
59	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 584520.	2.2	11
60	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
61	Models of Prognostication in Chronic Myelomonocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 513-521.	1.2	9
62	â€œReal-lifeâ€™ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018, 53, 58-63.	1.3	7
63	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). <i>Blood Advances</i> , 2020, 4, 2996-2999.	2.5	7
64	Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. <i>Oncotarget</i> , 2016, 7, 39458-39472.	0.8	7
65	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. <i>Bone Marrow Transplantation</i> , 2022, 57, 949-958.	1.3	7
66	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
67	Prospective evaluation of metabolic syndrome and its features in a single-center series of hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2018, 97, 2471-2478.	0.8	5
68	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , 2020, 55, 2077-2086.	1.3	5
69	Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial). <i>Blood</i> , 2014, 124, 320-320.	0.6	5
70	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. <i>Blood</i> , 2016, 128, 4320-4320.	0.6	5
71	Diagnosis and management of chronic myelomonocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 31-36.	1.2	4
72	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e256-e262.	2.0	4
74	Critical concepts and management recommendations for cutaneous Tâ€cell lymphoma: A consensusâ€based position paper from the Italian Group of Cutaneous Lymphoma. <i>Hematological Oncology</i> , 2021, 39, 275-283.	0.8	4
75	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. <i>Blood</i> , 2014, 124, 530-530.	0.6	4
76	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	1.3	4
77	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4581-4581.	0.6	3
78	An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 413-421.	0.1	3
79	Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. <i>Thrombosis and Haemostasis</i> , 2021, , .	1.8	3
80	Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition. <i>Transplantation</i> , 2019, 103, e48-e51.	0.5	2
81	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 328.e1-328.e6.	0.6	2
82	Myelodysplastic/Myeloproliferative Neoplasms. , 2019, , 561-568.		2
83	Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial). <i>Blood</i> , 2018, 132, 1019-1019.	0.6	2
84	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. <i>Blood</i> , 2013, 122, 2059-2059.	0.6	2
85	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. <i>Blood</i> , 2013, 122, 2094-2094.	0.6	2
86	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R). <i>Blood</i> , 2014, 124, 531-531.	0.6	2
87	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	1.3	2
88	Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. <i>Leukemia and Lymphoma</i> , 2022, 63, 2743-2746.	0.6	2
89	OC-014â€...Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisation alone in Crohnâ€™S Disease. <i>Gut</i> , 2013, 62, A6.2-A6.	6.1	1
90	Uncommon Breast Malignancies: Presentation Pattern, Prognostic Issue and Treatment Outcome in an Italian Single Institution Experience. <i>Tumori</i> , 2013, 99, 39-44.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies. <i>Platelets</i> , 2019, 30, 1053-1056.	1.1	1
92	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , 2018, 132, 3404-3404.	0.6	1
93	Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation. <i>Blood</i> , 2010, 116, 3043-3043.	0.6	1
94	Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome. <i>Blood</i> , 2014, 124, 4633-4633.	0.6	1
95	Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience. <i>Blood</i> , 2019, 134, 2042-2042.	0.6	1
96	A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 978-982.	0.2	1
97	Lettera al Direttore. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 197-197.	0.2	0
98	OP0025...Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis is Effective in Inducing Prolonged Remission of Disease Activity: Results from Long-Term Follow-Up. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 69.1-69.	0.5	0
99	SAT0471...Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis is More Effective Than Conventional Therapies in Inducing Disease Remission and Prolonging Survival: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 831.2-831.	0.5	0
100	Gv<sc>HD</sc> prophylaxis in nonhaploidentical allogeneic peripheral blood stem cell transplantation: beyond the standard to prevent relapse in patients with high-risk chronic lymphoproliferative diseases?. <i>European Journal of Haematology</i> , 2016, 96, 7-8.	1.1	0
101	DOP057 ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S070-S071.	0.6	0
102	Long-term remission of relapsed subcutaneous panniculitis-like T-cell lymphoma with cyclosporine A: A case report. <i>European Journal of Cancer</i> , 2018, 101, S24.	1.3	0
103	Allogeneic stem cell transplantation in advanced stage mycosis fungoides and SÅ©zary syndrome: 2018 update of the Milan experience. <i>European Journal of Cancer</i> , 2018, 101, S35-S36.	1.3	0
104	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. <i>Hemato</i> , 2020, 1, 10-22.	0.2	0
105	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , 2021, 2, 79-88.	0.2	0
106	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
107	In Vitro Colony Growth, RAS Genes Sequencing, and Expression of Bcl-2 and Bax Proteins in Chronic Myelomonocytic Leukemia.. <i>Blood</i> , 2004, 104, 2379-2379.	0.6	0
108	Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.. <i>Blood</i> , 2007, 110, 4196-4196.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Factors affecting prognosis in myelofibrosis. F1000 Medicine Reports, 2009, 1, .	2.9	0
110	New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia. Blood, 2010, 116, 1835-1835.	0.6	0
111	Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 4644-4644.	0.6	0
112	Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience. Blood, 2015, 126, 4403-4403.	0.6	0
113	Tyrosin-Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2015, 126, 5148-5148.	0.6	0
114	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). Blood, 2016, 128, 3473-3473.	0.6	0
115	Long-Term Outcome of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mycosis Fungoides and S�zary Syndrome: The Milan Experience. Blood, 2018, 132, 4655-4655.	0.6	0
116	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2182-2182.	0.6	0
117	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 4390-4390.	0.6	0
118	PF758�MULTI�CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST�TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS. HemaSphere, 2019, 3, 333.	1.2	0
119	Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and S�zary Syndrome: A Report of Four Consecutive Cases from a Single Center. Blood, 2019, 134, 5744-5744.	0.6	0
120	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). Blood, 2021, 138, 3959-3959.	0.6	0
121	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. Blood, 2021, 138, 3953-3953.	0.6	0
122	Simultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience. Blood, 2020, 136, 2-3.	0.6	0
123	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. Blood, 2020, 136, 39-40.	0.6	0
124	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2020, 136, 3-4.	0.6	0